Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

NextCure  Inc

2US
Current price
1.2 EUR -0.074 EUR (-5.79%)
Last closed 1.33 USD
ISIN US65343E1082
Sector Healthcare
Industry Biotechnology
Exchange Frankfurt Exchange
Capitalization 38 886 360 USD
Yield for 12 month +12.71 %
1Y
3Y
5Y
10Y
15Y
2US
21.11.2021 - 28.11.2021

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. Address: 9000 Virginia Manor Road, Beltsville, MD, United States, 20705

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-3 684 000 USD

Last Year

-4 480 000 USD

Current Quarter

-701 000 USD

Last Quarter

-940 000 USD

Key Figures 2US

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -60 403 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -31.09 %
PEG Ratio
Return On Equity TTM -54.75 %
Wall Street Target Price 5 USD
Revenue TTM
Book Value 3.05 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100 %
Dividend Yield
Gross Profit TTM -54 199 000 USD
Earnings per share -2.19 USD
Diluted Eps TTM -2.19 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics 2US

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 2US

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 2US

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.623
Price Sales TTM 9.5227
Enterprise Value EBITDA 0.5081
Price Book MRQ 0.4551

Financials 2US

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 2US

For 52 weeks

1 USD 2.57 USD
50 Day MA 1.43 USD
Shares Short Prior Month 76 093
200 Day MA 1.53 USD
Short Ratio 1.89
Shares Short 73 774
Short Percent 0.28 %